Minerva Neurosciences appointed Anthony Aliquo as its new Chief Accounting Officer and principal accounting officer effective August 10, 2026. Aliquo previously served as Vice President, Controller since November 2022 and brings over ten years of public accounting experience from BDO USA and Deloitte. Fred Ahlholm ceased serving as the principal accounting officer but will continue in his role as Chief Financial Officer. The Board approved an annual base salary increase for Aliquo to $296,696 and a performance bonus target of 35% of that salary, effective July 1, 2026. Minerva Neurosciences operates in the biotechnology industry, focusing on the development of therapies for neurological disorders.

Minerva Neurosciences reported financial results for the quarter ended June 30, 2026. The company recorded a GAAP net income of $17.5 million ($0.36 per basic share), driven by a $27.6 million non-cash gain on the change in fair value of its warrant liability; adjusted non-GAAP net loss was $7.8 million. Cash, cash equivalents, and marketable securities totaled approximately $75.4 million at June 30, 2026. The company confirmed that its confirmatory Phase 3 trial (C19 Study) for roluperidone is ongoing, with topline efficacy data expected in the second half of 2027. Minerva Neurosciences operates as a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders.